Valproate (All indications)

Cognitive developmental disorders/delay (> 6 years old)

R analysis
id Study   Lib. in paper Exposition period    Study type  Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12708
R53673
Bjørk (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 7.97 [5.07;12.52] C
excluded (control group)
64/2,421   27/7,950 91 2,421
ref
S12519
R53674
Bjørk (Valproate) (Controls unexposed NOS) (Mixed indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 4.77 [3.73;6.10]
excluded (control group)
64/2,421   16,384/4,463,879 16,448 2,421
ref
S12707
R53675
Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Diagnosis of intellectual disability (ID): mild ID (F70), moderate ID (F71), severe ID (F72), and profound ID (F73) (between 6.1 and 7.9 years old) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 4.20 [3.11;5.66] C 64/2,421   139/21,634 203 2,421
ref
S15275
R62802
Thomas (Valproate), 2022 Full-scale IQ - Wechsler Intelligence Scale for Children or Adult - Ages 13 to 21 years (mean of 16.5 ± 2.2 years) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 1.31 [0.38;4.52] -/33   -/11 - 33
ref
S9374
R53666
Bromley (Valproate), 2016 Full-scale IQ <85 (Wechsler Preschool and Primary Scale of Intelligence (WPPSI) / Wechsler Intelligence Scale for Children (WISC)) (5-9 years old) during pregnancy (anytime or not specified) retrospective cohort (registry) unexposed, sick Adjustment: No 4.11 [1.04;16.19] C 9/47   3/55 12 47
ref
S9371
R53663
Baker (Valproate) (Controls exposed to Lamotrigine, sick), 2015 Mean child Full scale IQ - Differential ability scales (DAS) (age mean >6 years old) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick excluded Adjustment: No extrapolated (cont. endpoint) 3.48 [1.49;8.14]
excluded (control group)
-/51   -/29 - 51
ref
S9372
R53664
Baker (Valproate) (Controls unexposed, disease free), 2015 IQ <85 - Differential ability scales (DAS) (age mean >6 years old) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: Yes 6.83 [3.02;15.45]
excluded (control group)
-/51   -/210 - 51
ref
S9373
R53665
Baker (Valproate) (Controls unexposed, sick), 2015 Mean child Full scale IQ - Differential ability scales (DAS) (age mean >6 years old) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 3.76 [1.54;9.19] -/51   -/25 - 51
ref
S9414
R53670
Meador (Valproate), 2013 IQ <85 (DAS) (at 6 years old) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: Yes 7.02 [1.42;34.66] C 8/49   2/74 10 49
ref
S9415
R53671
Nadebaum (Valproate), 2011 Full-scale child's IQ (WISC) during pregnancy (anytime or not specified) prospective cohort exposed to other treatment, sick Adjustment: No extrapolated (cont. endpoint) 5.19 [1.20;22.40] -/23   -/9 - 23
ref
S9421
R53678
Titze (Valproate) (Controls unexposed, disease free), 2008 Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) during pregnancy (anytime or not specified) prospective cohort unexposed, disease free excluded Adjustment: No Matched 19.40 [0.31;1195.39] C
excluded (control group)
0/3   0/49 0 3
ref
S9422
R53679
Titze (Valproate) (Controls unexposed, sick), 2008 Learning disability (IQ<70) (German versions of the revised Wechsler Intelligence Scales for children and for adults) during pregnancy (anytime or not specified) prospective cohort unexposed, sick Adjustment: No 1.53 [0.05;49.80] C 0/3   1/13 1 3
ref
S9428
R53672
Viinikainen (Valproate) b, 2006 Full Scale IQ (FIQ) < 1SD (Wechsler Intelligence Scale for Children (WISC III)) throughout pregnancy prospective cohort unexposed, sick Adjustment: No Matched 18.33 [0.88;380.72] C 5/13   0/13 5 13
ref
S9429
R53680
Vinten (Valproate), 2005 IQ score <69 (Wechsler Intelligence Scale for Children (WISC III)) (Aged between 6 and 16 years) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No 3.47 [1.14;10.56] C 9/41   6/80 15 41
ref
S9278
R53662
Adab (Valproate), 2004 Mean Full Scale IQ (Wechsler Intelligence Scale for Children (WISC)) (Aged between 6 and 16 years) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 1.26 [0.64;2.50] -/41   -/80 - 41
ref
S9401
R53667
Gaily (Valproate) (Controls unexposed, disease free), 2004 Full scale IQ (Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) or Wechsler Intelligence Scale for Children Revised (WISC-R)) 2nd and/or 3rd trimester prospective cohort unexposed, disease free excluded Adjustment: No extrapolated (cont. endpoint) 2.40 [0.85;6.75]
excluded (control group)
-/13   -/140 - 13
ref
S9402
R53668
Gaily (Valproate) (Controls unexposed, sick), 2004 Full scale IQ (Wechsler Preschool and Primary Scale of Intelligence Revised (WPPSI-R) or Wechsler Intelligence Scale for Children Revised (WISC-R)) 2nd and/or 3rd trimester prospective cohort unexposed, sick Adjustment: No extrapolated (cont. endpoint) 1.82 [0.59;5.59] -/13   -/45 - 13
ref
Total 11 studies 2.99 [2.00;4.48] 246 2,735
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022Bjørk, 2022 1 4.20[3.11; 5.66]2032,42125%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Thomas (Valproate), 2022Thomas, 2022 2 1.31[0.38; 4.52]-338%ROB confusion: criticalROB selection: criticalROB classification: criticalROB missing: criticalROB mesure: lowROB reporting: moderate Bromley (Valproate), 2016Bromley, 2016 3 4.11[1.04; 16.19]12477%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Baker (Valproate) (Controls unexposed, sick), 2015Baker, 2015 4 3.76[1.54; 9.19]-5112%ROB confusion: unclearROB selection: lowROB classification: moderateROB missing: moderateROB mesure: lowROB reporting: moderate Meador (Valproate), 2013Meador, 2013 5 7.02[1.42; 34.66]10495%ROB confusion: moderateROB selection: lowROB classification: lowROB missing: moderateROB mesure: lowROB reporting: low Nadebaum (Valproate), 2011Nadebaum, 2011 6 5.19[1.20; 22.40]-236%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: criticalROB mesure: lowROB reporting: moderate Titze (Valproate) (Controls unexposed, sick), 2008Titze, 2008 7 1.53[0.05; 49.80]131%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: moderateROB mesure: moderateROB reporting: moderate Viinikainen (Valproate) b, 2006Viinikainen, 2006 8 18.33[0.88; 380.72]5132%ROB confusion: seriousROB selection: lowROB classification: moderateROB missing: moderateROB mesure: lowROB reporting: moderate Vinten (Valproate), 2005Vinten, 2005 9 3.47[1.14; 10.56]15419%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: criticalROB mesure: lowROB reporting: moderate Adab (Valproate), 2004Adab, 2004 10 1.26[0.64; 2.50]-4116%ROB confusion: criticalROB selection: criticalROB classification: lowROB missing: criticalROB mesure: lowROB reporting: moderate Gaily (Valproate) (Controls unexposed, sick), 2004Gaily, 2004 11 1.82[0.59; 5.59]-139%ROB confusion: criticalROB selection: lowROB classification: moderateROB missing: criticalROB mesure: lowROB reporting: moderate Total (11 studies) I2 = 38% 2.99[2.00; 4.48]2462,7350.550.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Valproate) (Controls unexposed, sick) (Mixed indications; 2: Valproate; 3: Valproate; 4: Valproate) (Controls unexposed, sick; 5: Valproate; 6: Valproate; 7: Valproate) (Controls unexposed, sick; 8: Valproate) ; 9: Valproate; 10: Valproate; 11: Valproate) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.99[2.00; 4.48]2462,73538%NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Thomas (Valproate), 2022 Bromley (Valproate), 2016 Baker (Valproate) (Controls unexposed, sick), 2015 Meador (Valproate), 2013 Nadebaum (Valproate), 2011 Titze (Valproate) (Controls unexposed, sick), 2008 Viinikainen (Valproate) b, 2006 Vinten (Valproate), 2005 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 11 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 2.72[1.73; 4.29]2362,66347%NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Thomas (Valproate), 2022 Bromley (Valproate), 2016 Baker (Valproate) (Controls unexposed, sick), 2015 Titze (Valproate) (Controls unexposed, sick), 2008 Viinikainen (Valproate) b, 2006 Vinten (Valproate), 2005 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 9 exposed to other treatment, sickexposed to other treatment, sick 5.96[2.03; 17.52]10720%NAMeador (Valproate), 2013 Nadebaum (Valproate), 2011 2 Tags Adjustment   - No  - No 2.85[1.87; 4.35]2362,68641%NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Thomas (Valproate), 2022 Bromley (Valproate), 2016 Baker (Valproate) (Controls unexposed, sick), 2015 Nadebaum (Valproate), 2011 Titze (Valproate) (Controls unexposed, sick), 2008 Viinikainen (Valproate) b, 2006 Vinten (Valproate), 2005 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 10   - Yes  - Yes 7.02[1.42; 34.66]1049 -NAMeador (Valproate), 2013 1 Controls   - epilepsy indication  - epilepsy indication 4.20[3.11; 5.66]2032,421 -NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 1 extrapolated (cont. endpoint)extrapolated (cont. endpoint) 2.06[1.19; 3.56]-16131%NAThomas (Valproate), 2022 Baker (Valproate) (Controls unexposed, sick), 2015 Nadebaum (Valproate), 2011 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 5 MatchedMatched 18.33[0.88; 380.72]513 -NAViinikainen (Valproate) b, 2006 1 All studiesAll studies 2.99[2.00; 4.48]2462,73538%NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Thomas (Valproate), 2022 Bromley (Valproate), 2016 Baker (Valproate) (Controls unexposed, sick), 2015 Meador (Valproate), 2013 Nadebaum (Valproate), 2011 Titze (Valproate) (Controls unexposed, sick), 2008 Viinikainen (Valproate) b, 2006 Vinten (Valproate), 2005 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 110.550.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.25.32.1310.000Bjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022Thomas (Valproate), 2022Bromley (Valproate), 2016Baker (Valproate) (Controls unexposed, sick), 2015Meador (Valproate), 2013Nadebaum (Valproate), 2011Titze (Valproate) (Controls unexposed, sick), 2008Viinikainen (Valproate) b, 2006Vinten (Valproate), 2005Adab (Valproate), 2004Gaily (Valproate) (Controls unexposed, sick), 2004

Asymetry test p-value = 0.6218 (by Egger's regression)

slope=1.3227 (0.2538); intercept=-0.3288 (0.6437); t=0.5108; p=0.6218

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 9401, 9421, 9371, 9372, 12708, 12519

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 4.77[3.79; 5.99]16,4482,4880%NABjørk (Valproate) (Controls unexposed NOS) (Mixed indications), 2022 Baker (Valproate) (Controls unexposed, disease free), 2015 Titze (Valproate) (Controls unexposed, disease free), 2008 Gaily (Valproate) (Controls unexposed, disease free), 2004 4 unexposed, sick controlsunexposed, sick controls 2.72[1.73; 4.29]2362,66347%NABjørk (Valproate) (Controls unexposed, sick) (Mixed indications), 2022 Thomas (Valproate), 2022 Bromley (Valproate), 2016 Baker (Valproate) (Controls unexposed, sick), 2015 Titze (Valproate) (Controls unexposed, sick), 2008 Viinikainen (Valproate) b, 2006 Vinten (Valproate), 2005 Adab (Valproate), 2004 Gaily (Valproate) (Controls unexposed, sick), 2004 9 exposed to other treatment, sick controlsexposed to other treatment, sick controls 6.55[4.50; 9.52]1012,5440%NABjørk (Valproate) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2022 Baker (Valproate) (Controls exposed to Lamotrigine, sick), 2015 Meador (Valproate), 2013 Nadebaum (Valproate), 2011 40.510.01.0